WaveMan
WaveMan · Company
AEON · Aeon Biopharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AEON AEON Biopharma (AEON) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001837607
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter

What the filings say about AEON

Insiders, 180 days
+$243.5K net bought
1 buyer

AEON Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AEON Biopharma, Inc. insiders bought a net $243.5K of stock across 5 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
LYNCH TIMOTHY P
BUY
2026-08-21 SECtraded 2026-08-19
1,150,000
$243.5K
+26.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 17.7% of the 6,500,000 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider LYNCH TIMOTHY P bought about $243.5K of AEON on Aug 19, 2026, the largest insider purchase at the company on our record; 9 funds added in the latest 13F quarter.
FISCHER JOST
Director
BUY
2025-05-23 SECtraded 2025-05-21
60,000
$29.4K
-59.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 20, 2025.
  • +48.3% median (+48.3% mean) 90-day return after 2 previous buys.
  • The trade is 22.5% of the 266,785 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FISCHER JOST bought about $29.4K of AEON on May 21, 2025; 9 funds added in the latest 13F quarter.
FISCHER JOST
Director
BUY
2025-05-21 SECtraded 2025-05-20
60,000
$30.6K
-54.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 19, 2025.
  • The trade is 29.0% of the 206,785 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FISCHER JOST bought about $30.6K of AEON on May 20, 2025, the largest insider purchase at the company on our record; 9 funds added in the latest 13F quarter.
FISCHER JOST
Director
BUY
2025-05-21 SECtraded 2025-05-19
50,000
$25.0K
-54.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 34.1% of the 146,785 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FISCHER JOST bought about $25.0K of AEON on May 19, 2025, the largest insider purchase at the company on our record; 9 funds added in the latest 13F quarter.
Strathspey Crown Holdings Group, LLC
SELL
2023-08-14 SECtraded 2023-08-11
7,380,394
$73.8M
-99.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 363.2% of the 2,031,773 shares held after it.
  • No other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Strathspey Crown Holdings Group, LLC sold about $73.8M of AEON on Aug 11, 2023, the largest insider sale at the company on our record; 9 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$243.5K over 180 days
+$243.5K over 90 days · +$243.5K of it by a 10%+ holder
more than 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.0% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 52% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AEON

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-75.7%12M
-81%-43%-5%+33%2025-102025-122026-022026-042026-062026-082026-10 2026-08-19 · LYNCH TIMOTHY P bought $243.5K2026-01-29 · Daewoong Co.,Ltd. ("DWC") filed a 5%+ stake (49.99%)2026-01-29 · Daewoong Pharmaceutical Co. Ltd ("DWP") filed a 5%+ stake (49.75%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AEON: institutional holders (13F)

13F holdings, latest reported quarter
Dauntless Investment Group, LLC
12,490,154 sh
$9.0M
GEODE CAPITAL MANAGEMENT, LLC
95,311 sh
$68.6K
VANGUARD CAPITAL MANAGEMENT LLC
90,529 sh
$65.1K
Blue Owl Capital Holdings LP
42,353 sh
$30.5K
Formidable Asset Management, LLC
20,024 sh
$19.7K

Congress trades in AEON

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Daewoong Co.,Ltd. ("DWC")
Activist 13D · 2026-01-29
49.99%
Daewoong Pharmaceutical Co. Ltd ("DWP")
Activist 13D · 2026-01-29
49.75%

AEON planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

AEON mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$36.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$65.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.5K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.3K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $243.5K bought by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AEON financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$13.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-621.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-3,607%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-110.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122023-07
Operating income-$12.8M$73.0Mn/an/a
Net income-$39.2M$42.0Mn/an/a
EPS (diluted)-3.9572.93n/an/a
Operating cash flow-$17.3M-$20.3Mn/an/a
Cash$3.0M$13.0K$5.2M$31.2M
SEC XBRL, fiscal years, as known on 2026-10-27

AEON Stock Sonar score 4/7 axes

Find similar shapesCompare

AEON ranks highest on insider conviction (69th percentile) and risk and compliance (42nd), and lowest on profitability (2nd), among Pharma & Biotech peers.

Profitability
2
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-621.7% · 4 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-3607% · 0 pct, sector of 576
Insider conviction
69
Inputs
  • Net Form 4 buying (codes P and S), 180d$243K · 81 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
14
Inputs
  • Funds adding, latest quarter9 · 14 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
42
Inputs
  • Short interest, % of float+9.0% · 42 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AEON filings, in plain words

Are AEON Biopharma insiders buying or selling AEON?

In the 180 days to 2026-10-27, AEON Biopharma insiders were net buyers, a net $243.5K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-27, AEON Biopharma insiders were net buyers of AEON, a net $243.5K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $243.5K, came from a holder of 10% or more rather than an officer or director. The latest 5% ownership filing is a 13D by Daewoong Co.,Ltd. ("DWC"), filed 2026-01-29, for 50.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies